Indications for: Fenofibrate Capsules
Adjunct to diet: in severe hypertriglyceridemia; and to reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.
Take with food. Hypertriglyceridemia: 67–200mg/day; adjust in 4–8 week intervals; max 200mg/day. Hypercholesterolemia, dyslipidemia: 200mg/day. Renal impairment (CrCl<50mL/min): initially 67mg/day. Discontinue if inadequate response after 2 months on max dose.
Fenofibrate Capsules Contraindications:
Severe renal impairment. Dialysis. Active liver disease. Primary biliary cirrhosis. Unexplained persistent liver dysfunction. Gallbladder disease. Nursing mothers.
Fenofibrate Capsules Warnings/Precautions:
Renal impairment. Monitor CBCs for first year; monitor liver function, discontinue if ALT (SGPT) levels >3xULN persist. Discontinue if markedly elevated CPK levels, myopathy, or gallstones occur. Pregnancy.
Fenofibrate Capsules Classification:
Fenofibrate Capsules Interactions:
Avoid statins. Potentiates oral anticoagulants (monitor). Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with immunosuppressants (eg, cyclosporine), other nephrotoxic drugs.
Abnormal liver function tests, elevated CPK, respiratory or GI effects, myopathy, cholelithiasis, pancreatitis, increased creatinine, rash; rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.
Formerly known under the brand name Lofibra.